Stocks · News reference
Evercore analyst Jonathan Miller has initiated coverage of Shattuck Labs with a 'Buy' rating and a price target of $10.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Shattuck Labs, Inc. announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including progress with SL-325 and SL-846.
Filed: 2026-11-05 AccNo: 0001628280-26-070613 Size: 267 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
UBS analyst Alice Nettleton initiates coverage on Shattuck Labs (NASDAQ:STTK) with a Buy rating and announces Price Target of $17.
Wedbush analyst David Nierengarten maintains Shattuck Labs (NASDAQ:STTK) with a Outperform and raises the price target from $11 to $14.
Analysts raised targets for ACN, SYNA, ATRC and MPC; cut targets for CSX, NKE, MKC and FHTX, with ATRC downgraded to Hold.
Needham analyst Joseph Stringer maintains Shattuck Labs (NASDAQ:STTK) with a Buy and raises the price target from $17 to $19.